Response was fairly neutral. To be expected. It would be unrealistic to think that the results from the first patient ( back In May this year) are not known, but the "escape clause" regarding needing to announce anything would be along the lines of ....... we need results from a cohort of trial enrollees, not just one, before making any judgement as to the viability of the technology and a subsequent announcement to the market. So the ASX reply today in reality can't get into specifics with regard partially complete cohort trial results to date, its just to early yet. Thats not to say something may be forthcoming in the near term. Fact is the recruiting and trialling is continuing suggesting to me the technology is showing positive results, otherwise they would have hit the pause button.
IBX Price at posting:
10.0¢ Sentiment: Hold Disclosure: Held
